SCHEMBL24314192

SCHEMBL24314192

CCOc1ccc(F)cc1S(=O)(=O)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.50
KDM4E B2RXH2 1/20 0.48
MAPT P10636 2/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 2/20 0.45
TSHR P16473 3/20 0.43
MRGPRX1 Q96LB2 5/20 0.43
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALPL P05186 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406327 0.87 TRPV4 (0.61) TRPV4KDM4EMAPTLMNAALDH1A1
SCHEMBL29579920 0.83 CA12 (0.54) KDM4EMAPTLMNAALDH1A1NPSR1
SCHEMBL22588072 0.83 CA12 (0.54) KDM4EMAPTLMNAALDH1A1NPSR1
SCHEMBL29580235 0.83 SMN1; SMN2 (0.51) TRPV4KDM4EALDH1A1HTTTSHR
SCHEMBL20304580 0.83 SMN1; SMN2 (0.51) TRPV4KDM4EALDH1A1HTTTSHR
SCHEMBL7870540 0.81 TSHR (0.58) TRPV4MAPTALDH1A1NPSR1TSHR
SCHEMBL2703971 0.81 TSHR (0.62) TRPV4MAPTLMNAALDH1A1NPSR1
SCHEMBL29959795 0.81 TSHR (0.58) TRPV4MAPTALDH1A1NPSR1TSHR
SCHEMBL34468880 0.81 TSHR (0.58) TRPV4KDM4ELMNAALDH1A1NPSR1
SCHEMBL1127669 0.81 KDM4E (0.59) TRPV4KDM4ELMNAHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331719-A1 Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same OPTIKIRA LLC (US) 2023-10-19 US disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331719-A1 Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same XBP1, ERN1, ERN2 TRPV4 2071/4885KDM4E 825/4885MAPT 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.